Alnylam Pharmaceuticals | ALNY - Current Liabilities



Alnylam Pharmaceuticals reported $1.3B in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
Agios Pharmaceuticals USD 70.41M 18.04M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 225.22M Jun/2025
Amgen USD 20.48B 2.53B Jun/2025
Arrowhead Research USD 194.53M 26.01M Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Incyte USD 1.28B 608.18M Jun/2025
Ionis Pharmaceuticals USD 897.24M 646.94M Jun/2025
Moderna USD 1.57B 32M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
Novartis USD 31.71B 3.02B Jun/2025
PTC Therapeutics USD 627.81M 32.42M Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Sanofi 29.06B 103M Jun/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
Takeda JPY 2.17T 336.94B Jun/2025
Tectonic Therapeutic USD 11.36M 250K Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025
Xencor USD 96.08M 7.65M Jun/2025